Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
LutatheraⓇ Ph3 NETTER-2 results highlight the potential for
radioligand therapy (RLT) in earlier disease settings
INNOVATION
Demonstrated clinically meaningful and statistically
significant benefit in first line setting
■ Met primary endpoint of improvement in PFS and key secondary
endpoint of ORR
NETTER-2 supports potential acceleration
of treatment with RLT to 1L
~170k NET patients in US; GEP-NET represent 55-70%
"
Safety consistent with well-established profile of LutatheraⓇ
R
2:1
LutatheraⓇ 7.4 GBq Q8W x 4
PD
+ octreotide LAR 30 mg
Somatostatin Analogs (SSAs)
1L
>50% treated GEP-NET patients
in 1L, treated with SSAS
LutatheraⓇ; everolimus; SutentⓇ
2L
~30% of treated patients in 2L, where
LutatheraⓇ sees most of its use today
Follow-up
visits every
Captem; LutatheraⓇ; everolimus
10-15% of patients in 3L
3L
6 months
for 3 years
Captem; other chemo; everolimus
~5% of patients in 4L
4L
High-dose octreotide LAR
(60 mg) Q4W
PD
GEP-NET - gastroenteropancreatic neuroendocrine tumors.
21 Investor Relations | Q3 2023 Results
Next steps
Full data to be presented at upcoming medical meeting and provided
to guideline committees
NOVARTIS | Reimagining MedicineView entire presentation